risk of developing alzheimer’s disease in persons with mci survival curve of persons characterized...
TRANSCRIPT
![Page 1: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/1.jpg)
Alzheimer’s Disease Prevention Initiative
No Disease,No Symptoms
Early BrainChanges,
No Symptoms
Mild MemoryLoss
Mild, Moderate and Severe Impairment
Disease ProgressionDisease Progression
Mild Cognitive
Impairment
Pre-symptomatic
ADNormal AD
PrimaryPrevention
SecondaryPrevention Treatment
![Page 2: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/2.jpg)
Risk of Developing Alzheimer’s Disease in Persons with MCI
Survival curve of persons characterized as having a mild cognitive impairment for 6 years. Approximately 80% have converted to dementia during this time.
Peterson RC, et al., Arch Neurol. 58:1985-1992, 2001.
![Page 3: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/3.jpg)
Normal, 75 years old
Alzheimer’s disease, 75 years old
Volume of Hippocampus and Rate of Shrinkage Predicts Crossover from MCI to AD
Percent Annual Decline in Hippocampal Volume
0
0.5
1
1.5
2
2.5
3
3.5
4
Control MCI AD
StableDecliner
Jack CR, et al, Neurology 55: 484-489, 2000De Leon MJ, 1999
![Page 4: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/4.jpg)
PET Imaging of Amyloid Deposits in Alzheimer’s Disease vs Normal Controls
Source: Klunk, et al. Ann Neurol 2004: 55:306-319.
PET imaging with a novel tracer, Pittsburgh Compound-B (PIB), can provide quantitative information on amyloid deposits in living subjects.
![Page 5: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/5.jpg)
Current Drug Treatments for AD
• Acetylcholinesterase inhibitors for mild to moderate AD− Tacrine (Cognex)− Denepezil (Aricept)− Rivastigmine (Exelon)− Galantamine (Reminyl)
• Neuroprotective agent for moderate to severe AD− Memantine (Namenda)
![Page 6: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/6.jpg)
Funded AD Prevention and Selected Treatment Trials
Vitamins E, Aricept
Aspirin, Vitamin E
Estrogen
B-Carotene, Vit. E, C
Celecoxib, Naproxen
Ginkgo Biloba
Vitamin E, SeleniumSimvastatin
1998 1999 2000 2001 2002 2003 2004 2005 2006 2007 2008
Vitamin E, C, B6, B12, Folate, B-Carotene
April 2002
![Page 7: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/7.jpg)
Complementary & Alternative Therapies for AD
• Ginkgo Evaluation of Memory (GEM) study
• Clinical trial of huperzine• Traditional Asian medicines• High intensity light therapy
![Page 8: Risk of Developing Alzheimer’s Disease in Persons with MCI Survival curve of persons characterized as having a mild cognitive impairment for 6 years](https://reader036.vdocuments.mx/reader036/viewer/2022062717/56649e2b5503460f94b1a0fd/html5/thumbnails/8.jpg)
REACH II Intervention
The REACH II intervention is a multi-component
intervention designed to address five areas
linked to caregiver risk profile:
• Safety• Social Support• CR Problem Behaviors• Emotional well-being• Self-care and Health Behaviors